Agenovir Corp., of South San Francisco, named Dirk Thye CEO.
Anthera Pharmaceuticals Inc., of Hayward, Calif., named J. Craig Thompson CEO, and Paul Truex executive chairman and chairman of the board.
Asceneuron SA, of Lausanne, Switzerland, named J. Michael Ryan chief medical officer.
Celldex Therapeutics Inc., of Hampton, N.J., appointed Theresa LaVallee senior vice president, regulatory and precision medicine.
Compugen Ltd., of Holon, Israel, named Kirk A. Christoffersen senior vice president, corporate and business development. He will be based in South San Francisco.
Cymabay Therapeutics Inc., of Newark, Calif., added Robert Booth and Caroline Loewy to its board.
Critical Outcome Technologies Inc., of London, Ontario, appointed Alison Silva CEO, effective Jan. 1, 2017.
Egalet Corp., of Wayne, Pa., added Robert P. Roche Jr. to its board.
Enterome Bioscience SA, of Paris, appointed Jai Patel chief medical officer, and added Roger J. Garceau to its board.
Exelixis Inc., of South San Francisco, appointed Susan Hubbard executive vice president of public affairs and investor relations, and Stefan Krauss vice president of business development.
F2G Ltd., of Manchester, U.K., appointed John H. Rex chief medical officer.
Integra Lifesciences Holdings Corp., of Plainsboro, N.J., named Robert T. Davis Jr. corporate vice president and president, orthopedics and tissue technologies; Dan Reuvers corporate vice president and president specialty surgical solutions; and Glenn Coleman, who is currently corporate vice president, chief financial officer and principal accounting officer, in addition will assume oversight of the international business.
Invivo Therapeutics Holdings Corp., of Cambridge, Mass., appointed Melanie Morel-Ferris interim chief financial officer, effective Jan. 1, 2017.
Kiadis Pharma NV, of Amsterdam, the Netherlands, appointed Arthur Lahr chief operating officer and CEO designate, effective Jan. 1, 2017.
Lysogene SAS, of Paris, added David Schilansky to the board.
Mission Therapeutics Ltd., of Cambridge, U.K., appointed Colin Goddard non-executive chairman, effective Jan. 1, 2017, and named Michael Moore deputy chairman.
Nurix Inc., of San Francisco, added Robert Tjian to its board.
Rani Therapeutics Inc., of San Jose, added Maulik Nanavaty to its board.
Spark Therapeutics Inc., of Philadelphia, appointed John Furey chief operating officer.
Spotlight Innovation Inc., of West Des Moines, Iowa, appointed Chitra Edwin senior vice president of regulatory affairs and compliance.
Steadymed Ltd., of San Ramon, Calif., named Carl Hicks Jr. vice president of PH patient advocacy and community relations.